Primary Immunodeficiency Diseases (PID) Clinical Trial
Official title:
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration. Following a discussion with the FDA at the end of July 2012, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up. During this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was at the discretion of the participant and the investigator.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277313 -
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
|
Phase 3 | |
| Completed |
NCT03716700 -
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
|
||
| Active, not recruiting |
NCT05513586 -
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
|
Phase 3 | |
| Recruiting |
NCT05986734 -
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
|
||
| Completed |
NCT00546871 -
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05755035 -
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
|
Phase 2/Phase 3 | |
| Completed |
NCT02593188 -
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
|
||
| Completed |
NCT03116347 -
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
|
Phase 4 | |
| Completed |
NCT00157079 -
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
|
Phase 3 | |
| Completed |
NCT01412385 -
Immune Globulin Subcutaenous (Human), 20%
|
Phase 2/Phase 3 | |
| Completed |
NCT00161993 -
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
|
Phase 2 | |
| Completed |
NCT01175213 -
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT01218438 -
Phase 2/3 Study of IGSC, 20% in PIDD
|
Phase 2/Phase 3 | |
| Completed |
NCT05150340 -
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
|
Phase 3 | |
| Not yet recruiting |
NCT06076642 -
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00782106 -
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06150534 -
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
|
||
| Completed |
NCT00814320 -
Gammagard Liquid and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT04346108 -
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
|
Phase 3 |